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Spinal muscular atrophy (SMA) is a clinically and genetically heterogeneous disease characterized by the degeneration of lower motor
neurons. The most frequent form is linked to mutations in SMN1. Childhood SMA associated with progressive myoclonic epilepsy
(SMA-PME) has been reported as a rare autosomal-recessive condition unlinked to mutations in SMN1. Through linkage analysis, homo-
zygosity mapping, and exome sequencing in three unrelated SMA-PME-affected families, we identified a homozygous missense
mutation (c.125C>T [p.Thr42Met]) in exon 2 of ASAH1 in the affected children of two families and the same mutation associated
with a deletion of the whole gene in the third family. Expression studies of the c.125C>T mutant cDNA in Farber fibroblasts showed
that acid-ceramidase activity was only 32% of that generated by normal cDNA. This reduced activity was able to normalize the ceramide
level in Farber cells, raising the question of the pathogenic mechanism underlying the CNS involvement in deficient cells. Morpholino
knockdown of the ASAH1 ortholog in zebrafish led to a marked loss of motor-neuron axonal branching, a loss that is associated with
increased apoptosis in the spinal cord. Our results reveal a wide phenotypic spectrum associated with ASAH1 mutations. An acid-
ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint
pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype
restricted to the CNS and starting with lower-motor-neuron disease.Introduction
Childhood spinal muscular atrophy (SMA [MIM 253300,
MIM253550,MIM253400, andMIM271150]) is a clinically
and genetically heterogeneous group of inherited neuro-
muscular disorders characterized by the degeneration of
motor neurons of the spinal cord and leading to progressive
atrophyof skeletalmuscles andparalysis. Themost frequent
form is inherited as an autosomal-recessive trait result-
ing from mutations in survival of motor neuron 1 (SMN1
[MIM 600354]).1 The other forms of SMA are a genetically
heterogeneous group of rare disorders differing by their
mode of inheritance, the topography of the muscle deficit,
or their association with other neurological abnormalities.
Progressive myoclonic epilepsy (PME) represents a
heterogeneous group of epilepsies characterized by myoc-
lonic and generalized seizures with progressive neurolog-
ical deterioration. PME can occur as a pure form such as
Lafora disease (MIM 254780), Unverricht-Lundborg type
disease (MIM254800), andmyoclonic epilepsywith ragged
red fibers (MERRF [MIM 545000]) or can be associated
with neuronal ceroid lipofuscinosis (NCL [MIM 256730]),
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TA rare variant has been reported to associate lower-
motor-neuron disease with progressive myoclonic epilepsy
(SMA-PME) in childhood. This condition is inherited as an
autosomal-recessive trait. Jankovic and Rivera2 were the
first to report this association as a clinically separate entity.
Haliloglu et al.3 reported two additional families affected
by a syndrome characterized by severe and progressive my-
oclonic epilepsy and lower-motor-neuron disease proven
by electrophysiological and muscle-biopsy findings. The
facts that extensive metabolic investigations were normal
and that SMN1 mutations were ruled out indicate that
the association between PME and SMA represents a sepa-
rate clinical and genetic entity.
In this report, we combined exome sequencing and
whole-genome scanning with the use of SNP microarrays
to identify the genetic cause of SMA-PME in three unre-
lated families.
Subjects and Methods
Families
The first affected child, born from a first-degree consanguineous
Turkish family (family D, Figure 1) consisting of three affectedof Paris 11, Biomedical Institute of Bicetre, Le Kremlin-Biceˆtre 94276, France;
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Figure 1. Pedigrees and Linkage Anal-
ysis in SMA-PME-Affected Families
(A) Pedigrees of SMA-PME-affected fami-
lies. The numbers denote individuals
whose DNA samples were available for
genetic analysis. Linkage analysis and
homozygosity mapping were performed
in families D and ITA.
(B) Combined results of linkage analysis
of families D and ITA show a maximum
LOD score Zmax ¼ 2.7 at q ¼ 0.0. The
x axis represents genetic distance in cM,
and the y axis represents LOD scores.siblings and one unaffected sibling, developed progressive walking
difficulties, frequent falls, and a tremor in her hands from the age
of 5 years. Early developmental milestones were normal, and she
was able to walk at the age of 14 months. Physical examination
revealed proximal weakness and muscular atrophy. A creatine
kinase (CK) test was normal. Electromyography (EMG) showed a
chronic denervation process. By the age of 7 years, she began to
have brief myoclonic seizures without losing consciousness. An
electroencephalograph (EEG) showed slow and sharp bilateral
waves of 3–4 cycles/s. Repeated EEGs showed subcortical-
myoclonic epileptiform abnormalities sensitive to hyperventila-
tion. When the patient was 11 years old, muscle biopsy showed
neurogenic atrophy but no changes suggestive of a mitochondrial
disorder. The disease was progressive and caused recurrent lung
infections. She died at the age of 13 years. The second and third
affected children (IV-1 and IV-2, Figure 1,) had very similar symp-
toms, including myoclonic epilepsy and muscle weakness result-
ing from a denervation process. The disease course was progres-
sive, and both died at 17 years of age.
In this family, lysosomal screening tests for hexosaminidase A,
examination of peripheral blood leukocytes for a possible NCL,
and mitochondrial-DNA mutational analysis for MERRF were
negative. Fundoscopic examination, electroretinography, and
skin biopsy were normal. SMN1 copy number was normal. Brain
magnetic resonance imaging (MRI) of the three affected siblings
was normal.
The second family (family ITA, Figure 1) consisted of two
affected sisters born to unrelated healthy Italian parents. They
had normal motor and intellectual milestones. At 4 (II-1, Figure 1)
and 5 years of age (II-2), they developed progressive muscle weak-
ness of the lower and then upper limbs. Around age 12, both had
generalized epileptic seizures, numerous brief episodes of loss of
consciousness, and myoclonic jerks. Both affected children lost
the ability to walk at 17 years of age. Both sisters showed mild
facial weakness and difficulty swallowing, fasciculations of the
tongue, muscle weakness, absent deep-tendon reflexes, severe
scoliosis, and subsequent respiratory insufficiency. EMG and
muscle biopsies showed a denervation process, and brain MRI
was normal.
In the third family (family ITB, Figure 1), the affected girl (II-1)
was born to unrelated healthy Italian parents. Early develop-6 The American Journal of Human Genetics 91, 5–14, July 13, 2012mental milestones were normal. Progres-
sive muscle weakness started at the age
of 5 years. Around the age of 10 years,
the girl began having brief episodes of
loss of consciousness usually accompanied
by myoclonic jerks of the upper limbs.
When she was 11 years old, a neurologicalexamination showed diffuse muscle atrophy, mild facial weakness
and difficulty swallowing, and fasciculations of the tongue. The
affected child died from pneumonia at the age of 15 years. EMG
and muscle biopsy showed evidence of a denervation-reinnerva-
tion process. Brain MRI performed when she was 10 years
old showed no significant abnormalities. Between the ages of 10
and 14 years of age, her EEG recordings showed normal back-
ground activity and paroxysmal activity that consisted—in
frequent diffuse bursts—of sharp waves and poly-spike and wave
complexes that were present both in conscious wakefulness and
non-rapid-eye-movement sleep stages 1 and 2. Neither skin nor
joint abnormalities were reported in these affected individuals.
In accordance with the ethical standards of the institutional
review boards at CPP Iˆle de France, DNA samples from affected
individuals and their parents were collected after written informed
consent was given.
Genome-wide Linkage Analysis
Whole-genome SNP scanning was carried out according to the
Affymetrix 250K GeneChip Mapping Assay manual. Multipoint
linkage analysis and homozygosity mapping of SNP data applied
to the whole genome were performed with Alohomora4 and
Merlin software5 with the following parameters: autosomal-reces-
sive inheritance, 100% penetrance, and a 1:1,000 disease gene
frequency in the population.
Genome-Wide Human SNP Nsp/Sty Assay Kit 6.0 was used for
copy-number examination of the ASAH1 (MIM 613468) locus
according to the Affymetrix SNP 6.0 array protocol. Copy-number
variation (CNV) detection was performed by Birdseed in Affyme-
trix Genotyping console 4. A dataset of 90 HapMap samples was
added for the determination of CNV.
Exome Sequencing
The Illumina TruSeq DNA Sample Prep kit v.1 and the NimbleGen
SeqCap EZ Exome v.1 were used for library preparation and exome
enrichment, respectively. In brief, genomic DNA (3–5 mg) was frag-
mented in a Covaris S2 instrument. Fragmented DNA was pro-
cessed through enzymatic treatments of end repair, dA tailing,
and ligation to Illumina’s adapters. A 200–300 bp fraction was
excised from an agarose gel, and the adaptor-ligated library was
PCR amplified with Illumina PE primers for eight cycles. Products
(500 ng) were hybridized to the capture oligomers for 70 hr at
47C. Biotinylated hybrids were captured, and the enriched frac-
tion was eluted and amplified with 14 additional PCR cycles.
The pre- and post-capture libraries were compared by quantitative
PCR for the determination of the relative fold enrichment of the
targeted sequences. The library was applied to an Illumina flow
cell for cluster generation. Sequencing was performed on a
Genome Analyzer IIx instrument with 75 bp paired-end reads
according to Illumina’s protocol.
Reads were aligned to the human reference genome sequence
(UCSC hg19, National Center for Biotechnology Information
[NCBI] build 37.3) via the Burrows-Wheeler Aligner (BWA)
program.6 Variants were selected with Samtools7 and were then
annotated with Annovar software.8 Reads with a mapping quality
score of at least 20 and at least 53 coverage were filtered against
dbSNP v.131. Intron-exon junctions, nonannotated variants
(including synonymous, nonsynonymous, and nonsense muta-
tions) in coding regions, or short coding insertions or deletions
were selected. The ratio of mutants to total reads was at least
20%. An autosomal-recessive model was applied. Finally, variants
mapping to the candidate regions as determined by linkage anal-
ysis were selected.Real-Time PCR Amplification of Genomic DNA
Real-time PCR amplification was conducted with the use of
genomic DNA on a 7300 Real-Time PCR system (Applied Biosys-
tems) with Power SYBR Green PCR Master Mix (Applied Biosys-
tems). Genomic deletion was defined when the ratio of tested
DNA to control DNA was equal to or less than 0.5. Real-time
PCR amplification of each sample was performed in duplicate
with primers within ASAH1 exons 1, 2, or 14 (Table S1, available
online). Albumin was used as an internal control (Table S1).Reverse-Transcription-PCR Amplification
Total RNAs were extracted by the TRI Reagent LS method (Sigma).
One microgram of RNA was used for synthesizing cDNA with the
use of random primers according to the manufacturer’s manual
(SuperScript III Reverse Transcriptase, Invitrogen) in a final
volume of 20 ml. Reverse-transcription PCR (RT-PCR) amplification
was carried out with 1.5 mMMgCl2, 0.6 U DNA Polymerase (Invi-
trogen), 0.2 mM of each primer, and 1 ml cDNA. After an initial
denaturation cycle at 94C for 5 min, 30 cycles were performed
and consisted of denaturation at 94C for 30 s, annealing at
60C for 1 min, and extension at 72C for 1 min; these cycles
were followed by a final extension at 72C for 7 min in an ABI
9700 Thermal Cycler (Applied Biosystems). RT-PCR products
were separated by agarose gel electrophoresis and labeled with
ethidium bromide.
For determining the effect of the mutation in exon 2 of ASAH1
on transcripts, PCR-amplification analysis of single-strand cDNA
was performed with a forward primer chosen in exon 1 and reverse
primers in exons 4, 5, or 6 (Table S1). As an internal control for
PCR amplification, b-actin cDNA was coamplified (Table S1).
Sanger sequencing was performed from the PCR products.Sanger Sequencing
PCR primer pairs were designed from genomic DNA to amplify
exon 2 of ASAH1 (Table S1). PCR amplification was carried out
with 1.5 mM MgCl2, 0.6 U DNA polymerase, 0.25 mM of each
primer, and 100 ng DNA. After an initial denaturation cycle at
94C for 5 min, 30 cycles were performed and consisted of dena-Tturation at 95C for 30 s, annealing at 60C for 1 min, and exten-
sion at 72C for 1 min; these cycles were followed by a final exten-
sion at 72C for 7 min in an ABI 9700 Thermal Cycler. PCR
products were then purified on P100 columns (Bio-Gel P-2 Gel
fine, Biorad) and were sequenced with the forward or reverse
primers and the Big Dye Terminator v.3.1 Cycle Sequencing Kit
(Applied Biosystems). The sequencing reaction products were
purified on G50 columns (Sephadex G-50 Superfine, GE Health-
care) and then migrated on an automated fluorescent DNA
sequencer (ABI Prism 3100 Genetic analyzer, Applied Biosystems).
The obtained DNA sequences were compared with published
sequences (BLAST, NCBI).Cloning of Mutant cDNA and Expression Studies
of Acid Ceramidase
Cell Lines and Transfections
The cDNA of ASAH1, corresponding to transcript variant 1
(RefSeq accession number NM_177924), was kindly provided by
Dr. J.A. Medin (University of Toronto, Canada) and subcloned
into pcDNA5/TO (Life Technologies).9 The c.125C>T mutation
was introduced into wild-type (WT) cDNA after the removal of
the BamHI-BsgI restriction fragment flanking the mutation and
the ligation of a BamHI-BsgI restriction fragment derived from
RT-PCR of the affected individual’s RNA with primers provided
in Table S1. The plasmid was transformed into DH5a-T1R E. coli
(Invitrogen). Sequencing of mutant cDNA confirmed the insertion
of the mutation and the lack of any other sequence changes. The
Farber fibroblast cell line is a SV40 large T-transformed cell line
derived from a Farber-disease-affected individual (MIM 228000)
with an acid-ceramidase-activity level that is less than 3.5% of
the control value.10,11 Cells were grown in a humidified 5% CO2
atmosphere at 37C in DMEM medium containing 10% fetal calf
serum and Glutamax (Life Technologies). Fibroblasts were trans-
fected with the use of either Lipofectamine 2000 (Life Technolo-
gies) or Superfect (QIAGEN). The pCMV/LacZ vector was cotrans-
fected with WT or mutant ASAH1 cDNA for the evaluation of the
efficiency of transient expression through bacterial b-galactosidase
activity. Acid-ceramidase activity was normalized to the protein
level and bacterial b-galactosidase activity. Cotransfection of
both nonrecombinant pcDNA5/TO and pCMV/LacZ vectors was
used as a blank.
Enzymatic Assays
Acid-ceramidase activity was assayed with Rbm14-12; bacterial
b-galactosidase activities were determined with 4-methylumbelli-
feryl-b-D-galactopyranoside as a substrate (Sigma) as previously
reported.9,12,13
Quantitation of Ceramide
After extraction of lipids, ceramide levels were determined with
the use of E. coli diacylglycerol kinase and [g32P]-ATP as previously
described.14Immunoblotting Experiments
Pellets of transfected cells were resuspended in 0.2 ml of ice-cold
lysis buffer (Cell Signaling Technology) and immunoblotted
with a rabbit polyclonal acid-ceramidase antibody (kindly pro-
vided by Drs. K. Sandhoff and H. Schulze, Bonn, Germany).
Immunoreactive proteins were detected with enhanced chemilu-
minescence (Pierce). The b-actin monoclonal antibody (Cell
Signaling Technology) was used as an internal control for loading.
The density of the bands was quantified with ImageJ (National
Institutes of Health).he American Journal of Human Genetics 91, 5–14, July 13, 2012 7
Knockdown of ASAH1 in Zebrafish with Antisense
Morpholino Oligonucleotides
Embryos were staged and cared for according to standard
protocols.15
Injections of Antisense Morpholino Oligonucleotides
Antisense morpholino oligonucleotides (MOs) were purchased
from Gene Tools. asah1b-MO (Table S1) was designed to target
the 50 UTR of asah1b mRNA (RefSeq NM_200577). The control
‘‘mismatch’’ morpholino (Table S1) had five nucleotides altered
along its sequence. Morpholinos were dissolved in water to a final
concentration of 0.6 mM; 1 nl of morpholino was injected into
1- to 4-cell-stage embryos as previously described.16
Immunohistochemistry
For immunostaining, embryos were fixed in 4% paraformaldehyde
and stained as whole mounts. The acetylated-tubulin antibody
(Sigma) was used at a 1:1,000 dilution. The znp-1 antibody (Devel-
opmental Studies Hybridoma Bank) was used at a dilution of 1:75.
Primary antibodies were detected with appropriate secondary
antibodies conjugated to Alexa 488 (Molecular Probes) at a 1:200
dilution.
Confocal Image Analysis
Image acquisition was performed with a Zeiss confocalmicroscope
and Zeiss LSM imaging software. Images were captured in z sec-
tions at 2 mm increments. Axonal-branch analysis was performed
offline with the ImageJ plugin NeuronJ and Adobe photoshop.
Analysis was restricted to fascicles ventral to the spinal cord
because labeling of spinal neuropil precluded the accurate exami-
nation of dorsal processes. Thus, axon branches of the rostral and
caudal primary motor neurons were included for analysis. Branch
patterns of five consecutive somites were analyzed per fish (three
are presented for each group).
Acridine-Orange Staining
Living zebrafish larvae were anesthetized with Tricaine (Sigma-
Aldrich), incubated in a solution of 3 mg/ml acridine orange
(Sigma-Aldrich) with Tricaine for 30 min, and then washed. For
imaging, fish were embedded in 1.2% low-melting agarose.
Statistics
Mean values and standard deviations (SDs) were calculated with
Microsoft Excel. Statistical analysis was performed with a Student’s
t test. p values < 0.05 were considered as significant.
Enzymatic assays and quantization of ceramide are described
above.Results
Genome-wide SNP Genotyping and Exome
Sequencing Identify ASAH1 Mutations in SMA-PME
To identify the disease locus, we conducted genome-wide
SNP genotyping by using the 250K NspI microarrays in
the two multiplex families (families D and ITA, Figure 1).
Multipoint linkage analysis of SNP data was performed
for each family, and homozygosity mapping was per-
formed for the consanguineous family (family D). Com-
bining linkage data from the two multiplex families re-
vealed two overlapping loci in chromosomal regions
8p22 and 13q12; each locus had a maximum LOD score
of Zmax ¼ 2.7 at q ¼ 0.0 (Figure 1). The sizes of the disease
loci in chromosomal regions 8p22 and 13q12 were
8.38 Mb and 4.46 Mb, respectively. The recombinant
events were observed between rs1510424 and rs78459538 The American Journal of Human Genetics 91, 5–14, July 13, 2012(chr8: 14,450,366–22,828,463; human genome build
37.3) and between rs6490964 and rs2479781 (chr13:
25,196,912–29,653,083). According to Map viewer
(NCBI), these intervals contained 97 annotated genes.
We performed Sanger sequencing of exons and intron-
exon junctions of candidate genes chosen on the basis of
their position and function. No mutations in ATP6V1B2
(MIM 606939), EGR3 (MIM 602419), LGI3 (MIM
608302), MTIF3, or NUPL1 (MIM 607615) were found in
the affected individuals.
We then performed exome sequencing by using the
DNA sample of one affected individual per family (IV-1
in family D, II-2 in family ITA, and II-1 in family ITB;
Figure 1). The median coverage of the targeted exomes
was 623, 713, and 733 in the affected individuals from
families D, ITA, and ITB, respectively. Nonannotated
variants mapping to the two candidate regions as deter-
mined by linkage analysis were selected. As a result, only
24, 23, and 26 variants remained candidates in affected
individuals from families D, ITA, and ITB, respectively.
ASAH1, located on chromosome 8, was the only gene
carrying nonannotated variants shared by the three un-
related affected individuals. The same missense mutation
(c.125C>T [p.Thr42Met]; RefSeq NM_177924.3) in exon
2 of ASAH1 was found in the three affected individuals.
Sanger sequencing of DNA samples confirmed that the
mutation was homozygous (or hemizygous) in the three
affected persons (Figure 2). The p.Thr42Met missense
substitution occurred at an evolutionarily conserved
amino acid among different species (Figure S1). This muta-
tion was absent in 95 ethnically matched controls.
c.125C>T was found at a very low frequency (2 out of
10,756 alleles) in the current Exome Variant Server data-
base (ESP5400). The possible impact of the p.Thr42Met
substitution on the function of acid ceramidase was calcu-
lated with Polyphen-2 software.17 This substitution is
predicted to be damaging on the basis of its high score
(0.969). Segregation analysis of the mutation was per-
formed in the three families. In families D and ITA, both
parents were heterozygous and affected siblings were
homozygous for this missense mutation (Figure 2). In
family ITB, the mother was heterozygous, whereas the
father harbored only a WT allele, suggesting either an
inherited or de novo deletion occurring at this locus
(Figure 2). We performed real-time PCR on DNA from
the affected individual in family ITB by using primers
located in exons 1, 2, and 14 of ASAH1. A heterozygous
deletion was observed in both the affected child and her
father, indicating that the affected child was compound
heterozygous for the c.125C>T mutation inherited from
the mother and for a whole-gene deletion inherited
from her father (data not shown). To refine the size of
the deletion found in the affected individual of family
ITB, we performed pangenomic analysis of her DNA by
using the Genome-Wide Human SNP Array 6.0 that had
an intermarker distance of less than 1 kb. A 55 kb
heterozygous deletion was found on chromosome 8
Figure 2. ASAH1 Mutations Identified in SMA-
PME-Affected Families
(A) Sanger sequencing of ASAH1 exon 2 (genomic
DNA) shows (1) a homozygous (or hemizygous)
c.125C>T mutation in affected individuals of
the three families (arrow); (2) a heterozygous
c.125C>T mutation in both parents of families
D and ITA and the mother of family ITB; and
(3) a WT allele only in the father of family ITB.
Reverse strands are shown.
(B) Copy-number and SNP analysis of the
affected child in family ITB shows a heterozygous
deletion of the whole gene. Dots indicate copy
number and SNP copy number (1 or 2). Vertical
bars indicate copy number (dark green) or SNPs
(light green). The horizontal red rectangular box
indicates the physical position of the heterozy-
gous deletion.from position 17,909,063 to 17,964,559 (Hg 19) and
included 24 copy-number and 51 SNP probes (Figure 2).
This deletion involves ASAH1 only. Among the 51 SNPs
mapping to the deleted region, 18 of them had a minor
allele frequency (MAF) >5% and revealed an identical
haplotype covering 31 kb in the affected individuals
of the three families. These data suggest that the
c.125C>T mutation occurred on a common ancestral
allele.
Because the c.125C>T mutation involves the last nucle-
otide of ASAH1 exon 2, binding sites for specific serine-and
arginine-rich proteins might be modified. In silico analysis
was performed with the ESEfinder program.18 The muta-
tion results in a higher score for the SC35 binding site.
To determine whether abnormal splicing might occur
in vivo and whether the mutation might result in aber-
rantly spliced products, we performed RT-PCR analysis of
ASAH1 from RNA extracted from blood leukocytes of the
affected individual from family ITB. RT-PCR products
from exon 1 to 4, 5, or 6 did not show any size difference
between the affected individual and controls (Figure S1).
Sequence analysis revealed that, compared to those of
the controls, the RT-PCR products of the affected indi-
vidual did not show any splice changes, indicating that
this mutation does not affect the splicing process of
ASAH1 exon 2 in the cell type analyzed no matter which
transcript variant it contains (isoform 1 or 2, Figure S1
and data not shown). To determine the pattern of expres-
sion of ASAH1 transcripts, we performed RT-PCR analysis
in various tissues, including lymphoblastoid cell lines
and spinal cord, skeletal-muscle, and liver tissue. TheThe American JourASAH1 transcript was expressed in all
tissues examined (Figure S1).
The p.Thr42Met Missense Substitution
Results in Acid-Ceramidase Deficiency
Because cell cultures from SMA-PME-
affected individuals were not available,
WT and c.125C>T mutant ASAH1 cDNAs
were cloned into the pcDNA5/TO expres-sion vector for functional studies. In order to assess the
functional effect of the observed ASAH1 missense muta-
tion, we transfected recombinant vectors into immortal-
ized fibroblasts derived from a Farber-disease-affected indi-
vidual with a very severe acid-ceramidase activity (less
than 3.5% of the control value).10 WT or mutant ASAH1
cDNA was cotransfected with the pCMV/LacZ vector.
Acid-ceramidase activity was then normalized to the
protein level and bacterial b-galactosidase activity. As
shown in Table 1, transient expression of the mutant
cDNA revealed that its acid-ceramidase activity was lower
than that of the WT cDNA (i.e., it was about 32% of the
control value). Similar results were observed with Super-
fect or Lipofectamine 2000 for transfection experiments
(data not shown).
To directly assess the enzyme activity toward its
natural substrate, i.e., ceramide, in living cells, we then
examined whether the expression of the mutated cDNA
in fibroblasts from a Farber-disease-affected individual
could result in clearance of the accumulated substrate.
Transient expression of either theWTor mutated sequence
led to a marked (and similar) reduction of the ceramide
storage (Table 1).
We performed immunoblotting experiments to charac-
terize the WT and mutant proteins in human cells. Farber
fibroblasts were transiently transfected with WT or
c.125C>T mutant ASAH1 cDNAs, and acid ceramidase
was analyzed by immunoblot analysis (Figure 3). The
substitution affects neither the level of the precursor
form nor its processing. However, the a-subunit amount
was mildly lower than the b-subunit amount.nal of Human Genetics 91, 5–14, July 13, 2012 9
Table 1. Acid-Ceramidase Activity and Ceramide Content in Farber Fibroblasts Expressing the p.Thr42Met Substitution
Transfected with:
Acid-Ceramidase
Activity (pmol/h/mg)
Acid Ceramidase/
b-Galactosidase 3 100
Ceramide Content
(pmol/mg)
Nothing 278 18,543
Transfection agent only 961 0.8 17,141
Empty pcDNA5/TO 528 5.2 19,206
pcDNA5/TO-ASAH1 14,194 90.9 5,401
pcDNA5/TO-ASAH1-C2 16,333 137 3,372
pcDNA5/TO-ASAH1-C3 18,694 176 4,460
pcDNA5/TO-ASAH1-P4 5,194 37.7 5,250
pcDNA5/TO-ASAH1-P6 5,417 53.8 4,413
Farber cells were cotransfected in the presence of lipofectamine with a vector encoding LacZ and pcDNA5/TO vectors carrying ASAH1 cDNA or not, and they were
cultured for 48 hr. The pcDNA5/TO-ASAH1, pcDNA5/TO-ASAH1-C2, and pcDNA5/TO-ASAH1-C3 plasmids carry the WT sequence, whereas the pcDNA5/
TO-ASAH1-P4 and pcDNA5/TO-ASAH1-P6 plasmids carry the mutant (c.125C>T) sequence. Acid-ceramidase and bacterial b-galactosidase activities and total
ceramide content were determined on cell lysates as described in the Material and Methods. Acid-ceramidase activity is expressed as pmol/h/mg of protein,
and ceramide level is expressed as pmol/mg of protein. Each determination was performed in duplicate. Note that the acid-ceramidase activity and ceramide
content in normal fibroblasts average 7,000–9,000 pmol/h/mg and 1,000–2,500 pmol/mg, respectively.Knockdown of ASAH1 in Zebrafish Embryos Leads
to Defective Motor Neurons
To analyze ASAH1 function in vivo, we used zebrafish as
a model and designed for the ASAH1 ortholog, asah1b, a
translation-blocking antisense MO (asah1b-MO) that tar-
gets regions in the 50 UTR of the mRNA.16 Asah1b has the
highest degree of homology (60%) with the ASAH1 prepro-
tein (RefSeq NP_808592), particularly at the N-terminus,
the region specific to the preprotein (variant 1). Embryos
injected with 0.6 pmole of a 5 base mismatch control MO
(referred to as ‘‘control 5 mis MO’’ below) were indistin-
guishable from uninjected, WT embryos (n ¼ 42; Figures
4A and 4B). However, by 48 hr postfertilization (hpf),
embryos injected with asah1b-MO (0.6 pmole) exhibited
defects, including a curved body (n ¼ 50; Figure 4C). To
assess whether the general integrity of the embryos was
affected, we analyzed cell death in living fish by incubation
in acridine orange,19 a dye that stains nucleic acids in dying
cells. Comparison of morphants with both controls at
48 hpf demonstrated a significant increase in apoptosis
in the spinal cord of morphants (n ¼ 8 embryos for each
group; WT versus control 5 mis MO: t ¼ 1.70 and
p ¼ 0.12; asah1b-MO versus WT: t ¼ 11.7 and p < 0.0001;
asah1b-MO versus control 5 mis MO: t ¼ 9.87 and
p < 0.0001) (Figures 4D–4G), whereas no increase in cell
death was detected elsewhere. These data suggest that
neurons indeed degenerate in the spinal cord of asah1b
morphants, whereas the general integrity of these embryos
remains intact.
We next wished to determine whether asah1b could be
involved in motor-axon development. To this end, we
abrogated asah1b expression throughout early develop-
ment with antisense MOs. We looked specifically at the
primary motor neurons, which are few in number (typi-
cally three per somite), that undergo axonogenesis at 17
hpf and innervate the majority of muscle fibers in a given
territory. To assess the developmental impact of asah1b10 The American Journal of Human Genetics 91, 5–14, July 13, 2012reduction on axons of primary motor neurons, we used
znp1 antibodies, panspecific markers of primary motor
axons.20 Although motor-axon branches of control-5-
mis-MO-injected fish were similar to those of WT fish at
48 hpf (Figures 4H–4L), striking changes occurred in the
asah1b morphants. Here, although motor axons appeared
to be shorter in the morphants, the difference was not
significant; however, there was a striking difference in
the number of collateral branches in the asah1b mor-
phants (n ¼ 25 fascicles in six different embryos for each
group; WT [18 5 1.59 branches per fascicle (bpf)] versus
control 5 mis Mo [17.8 5 1.5 bpf and p ¼ 0.821]; WT
versus asah1b-MO [6.065 2.2 bpf and p< 0.0001]; control
5 mis MO versus asah1b-MO [p < 0.0001]) (Figures 4K, 4L,
4M, and 4Q). To investigate whether the defect observed
here was specific to motor-neuron axonal branching or
was common to axonal projections in general, we used
the acetylated-tubulin antibody, a microtubule marker
that labels axonal projections. At 48 hpf, the posterior
lateral line nerve (PLLn) had already reached the tip end
of the tail in both controls and asah1b morphants (Figures
4N–4P). Thus, asah1b is required specifically for motor-
neuron axonal branching (and probably for other spinal-
cord neurons) but does not affect peripheral projections,
at least as indicated by the PLLn. This also shows that there
was no general delay in the development of themorphants
compared with controls.
To confirm whether the morphant phenotype resulted
from either knockout or knockdown of Asah1b, we deter-
mined the acid-ceramidase activity and ceramide content
of zebrafish embryos (Table 2). Comparison of morphants
with control zebrafish embryos revealed a significant
decrease but not abrogation of acid-ceramidase activity
in morphants (mean of 26%) without affecting ceramide
content, indicating that antisense MOs resulted in knock-
down of Asah1b in zebrafish. These data are consis-
tent with those found in transfected human cells and
Figure 3. Immunoblot Analysis of ASAH1
(A) Farber fibroblasts were either not tranfected (‘‘NT’’) or cotrans-
fected with LacZ and pcDNA5/TO expression vectors carrying the
ASAH1 cDNA or not (‘‘Empty’’). The pcDNA5/TO-ASAH1
(‘‘ASAH1’’), pcDNA5/TO-ASAH1-C2 (‘‘C2’’), and pcDNA5/TO-
ASAH1-C3 (‘‘C3’’) plasmids carry the WT sequence, whereas the
pcDNA5/TO-ASAH1-P4 (‘‘P4’’) and pcDNA5/TO-ASAH1-P6 (‘‘P6’’)
plasmids carry the mutant (c.125C>T) sequence. Forty-eight
hours later, cell extracts were analyzed by immunoblotting with
acid-ceramidase and b-actin antibodies.
(B) The density of the bands corresponding to the precursor form
(55 kDa), the b-subunit (40 kDa), and the a-subunit (13 kDa) of
acid ceramidase was normalized to that of b-actin and compared
to those of the WT protein (‘‘ASAH1’’). Note the reduced amount
of the a-subunit in cells transfected with mutant cDNA.
(C) The acid-ceramidase and bacterial b-galactosidase enzyme
activities were determined on the same cell lysates as described
in Table 1.demonstrate that asah1b plays an essential role in motor-
neuron axonal branching and in the survival of spinal-
cord neurons.Discussion
Genome-wide linkage analysis combined with exome
sequencing in three families affected by childhood SMA-
PME allowed us to identify ASAH1 mutations as respon-
sible for this disease entity.
The main clinical feature of this condition is the onset of
motor deficits at the age of 3 years after normal develop-
mental milestones. Progressive muscle paralysis is caused
by the involvement of lower motor neurons and is deter-
mined by EMG and/or muscle biopsy. Myoclonic epilepsy
is then observed and is generally resistant to conventional
therapy. The disease course is progressive and leads to
respiratory muscle involvement and severe handicap or
death occurring before 20 years of age. Neither skin nor
joint abnormalities were noticed, and brain MRI was
normal. In families D and ITA, affected children are homo-Thzygous for the c.125C>Tmissensemutation. In family ITB,
the affected child carries the c.125C>T missense mutation
and a deletion of the whole gene. The deleterious effect of
the p.Thr42Met missense substitution on acid-ceramidase
activity and the marked defect of motor-neuron axonal
branching associated with a significant increase in
apoptosis in the spinal cord of asah1b morphants further
support the finding that ASAH1mutations are responsible
for SMA-PME.
Mutations of the same gene are responsible for Farber
disease, a very rare autosomal-recessive condition resulting
frommarked reduction or complete lack of lysosomal acid-
ceramidase activity.21 Farber disease manifests most
commonly between 2 weeks and 4 months of age and
has a unique triad of clinical manifestations: (1) painful
and progressively deformed joints, (2) subcutaneous
nodules, particularly near the joints and over pressure
points (lipogranulomata), and (3) progressive hoarseness
due to laryngeal involvement. The liver, spleen, lungs,
and heart are often involved, and the nervous system
can show accumulation of ceramides and gangliosides in
the neurons of the brain and spinal cord. The illness is
progressive and often leads to death at a mean age of
1.45 years in the classical form. A minority of affected
infants survive beyond 5 years of age. Diagnosis is
confirmed by an acid-ceramidase assay or by morphologic
and/or biochemical studies of biopsy or autopsy tissues.
None of the individuals with SMA-PME reported here
have the main clinical manifestations of Farber disease.
In addition, the first symptoms of SMA-PME appear later
(>3 years of age) and are restricted to the CNS, and death
occurs after 12 years. This might explain why Farber
disease and SMA-PME have not been suspected to be allelic
conditions so far.
Data on almost 80 Farber-disease-affected individuals in
a variety of ethnic groups have been reported.21 In vitro
residual activity of acid ceramidase is less than 10% in
Farber disease. The ceramide that accumulates in Farber
disease is primarily located in the lysosomes. Turnover
studies have shown that it results from the impaired
capacity of acid ceramidase to hydrolyze the ceramide
generated during the degradation of complex sphingoli-
pids. However, Samuelsson and Zetterstrom22 reported
on mildly affected individuals in whom liver, lung, or
brain ceramide levels were normal. Therefore, the role of
ceramide accumulation in the disease pathogenesis
remains unclear. In SMA-PME-affected individuals, we
found that the c.125C>T mutation causes residual acid-ce-
ramidase activity to be about one-third of that of normal
cells. Immunoblotting experiments showed that the
a-subunit amount was mildly lower than the b-subunit
amount, suggesting that the c.125C>T mutation that
occurs within the a-subunit might affect its stability and
result in reduced acid-ceramidase activity. Neither the
c.125C>T mutation nor the whole-gene deletion has
been reported in Farber disease. A homozygous missense
substitution (p.Tyr36Cys) has already been reported ine American Journal of Human Genetics 91, 5–14, July 13, 2012 11
Figure 4. Morpholino Knockdown of asah1b in Zebrafish
(A–C)Morphology of living embryos at 52 hpf.WTembryos, control-5-mis-MO-injected embryos, and embryos injected with 0.6 pmole
of asah1b-MO (asah1b morphants) are shown. Note the curved body shape that asah1b morphants show in comparison to the body
shape of both controls. Views are lateral, and the dorsal sides are at the top. The scale bar represents 200 mm.
(D–F) Side views of 48 hpf living zebrafish embryos stained with acridine orange (D); some single acridine-orange-positive neurons are
depicted by asterisks in WT embryos, control-5-mis-MO-injected embryos (E), or asah1b morphants (F). Asah1b morphants show
substantial cell death in the spinal cord (dashed lines), whereas both controls show only a low, basal number of apoptotic cells. The scale
bar represents 100 mm. The following abbreviation is used: sc, spinal cord.
(G) Bar chart depicting the mean number (5 SD) of acridine-orange-positive cells per surface unit for WT (2.665 0.74), control 5 mis
MO (3.835 1.34), and asah1b morphants (16.35 2.5) at 48 hpf. Data represent mean5 SD. ***p < 0.0001.
(H–M) The asah1bmorpholino decreases motor-axon collateral formation. Lateral views of znp1-antibody staining of controls (H and I)
and asah1b morphants (J) are shown at 48 hpf. znp1 labels motor axons (H, arrowheads). Tracings of motor-axon tracts ventral to the
spinal cord (K–M) are derived from panels directly above. Scale bars represent 50 mm. The following abbreviations are used: D, dorsal; V,
ventral; A, anterior; and P, posterior.
(N–P) Lateral views of acetylated-tubulin-expressing axons of the PLLn (arrow) in WT, control-5-mis-MO-injected embryos, and asah1b
morphants at 48 hpf. Axonal growth is similar in all groups; the PLLn reaches the tip end of the tail (arrows, n ¼ 10 per group).
(Q) Bar chart depicting the mean number (5 SD) of axon branches per fascicle for WT (185 1.59), control-5-mis-MO-injected embryos
(17.85 1.5), and asah1bmorphants (65 2.2) at 48 hpf. Comparedwith both controls, Asah1bmorphants show a significant decrease in
axonal branching. ***p < 0.0001.a classical form of Farber disease leading to less than 5% of
normal acid-ceramidase activity.21 Although the position
of p.Tyr36Cys is close to the p.Thr42Met substitution
found in SMA-PME-affected individuals, the marked differ-
ence in the level of acid-ceramidase activity in Farber
disease and SMA-PME might account for distinct and
later-onset clinical SMA-PME phenotypes.
Importantly, in addition to the unique triad of clinical
manifestations of Farber disease, lower-motor-neuron12 The American Journal of Human Genetics 91, 5–14, July 13, 2012involvement characterized by hypotonia and muscular
atrophy with diminished or lack of deep-tendon reflexes
was observed in 11 out 80 individuals with the classical
form of Farber disease at late stages of disease progression
(type 1).21 EMG showed signs of denervation. Salaam-
type seizures or infantile spasms were reported in two
affected individuals. The nervous system was abnormal
in all autopsied affected persons; an accumulation of
storage material was found in the neuronal cytoplasm,
Table 2. Acid-Ceramidase Activity and Ceramide Content in
Control and Farber Fibroblasts and in WT and Morphant Zebrafish
Embryos
Acid-Ceramidase
Activity
(pmol/h/mg)
Acid-
Ceramidase
Activity (%)
Ceramide
Content
(pmol/mg)
Experiment 1
Control fibroblasts 8,556 958
Farber fibroblasts 267 3.1% 8,004
Experiment 2
WT zebrafish-1 5,172 1,123
MO zebrafish-1 1,324 25.6% 637
MO zebrafish-2 561 10.8% 786
Experiment 3
WT zebrafish-2 7,319 885
MO zebrafish-3 3,064 41.9% 786
Each determination was performed in duplicate. The residual acid-ceramidase
activity (%) is shown as the ratio of mutant to WT activity within each set of
experiments. The following abbreviations are used: WT, wild-type; and MO,
morphant.particularly in the anterior horn cells of the spinal cord but
also in the brain-stem nuclei, basal ganglia, cerebellum,
retinal ganglion cells, and cortical neurons. These data
indicate that the CNS is progressively involved in Farber
disease. Consistent with these data, the fact that spinal
motor neurons show axonal-branching defects indicates
a marked and early-onset vulnerability of motor neurons
in response to ASAH1 knockdown in zebrafish embryos.
Our findings strongly suggest that although a dramatic
reduction of acid-ceramidase activity leads to Farber
disease, a very severe and early-onset disease characterized
by an involvement of joints, skin, and laryngeal tissues
and progressive neurological deterioration, a milder reduc-
tion of enzymatic activity leads to a later-onset of symp-
toms restricted to spinal-cord motor neurons and other
areas of the CNS. Several therapeutic strategies have been
undertaken for Farber disease. Allogeneic bone-marrow
transplant (BMT) has been performed in a 9.5-month-old
child with minimally symptomatic Farber disease.23 Ce-
ramidase activity in peripheral-blood leukocytes increased
from 6% to 44% by 6 weeks after BMT. By 6 months after
BMT, the subcutaneous lipogranulomata, contractures
and joint pains, and hoarseness of the voice had
completely resolved. However, the affected individual
developed progressive hypotonia, muscle weakness, loss
of head control, inability to sit unassisted, flexion contrac-
tures, opisthotonus, and tongue fasciculations.23 These
features are consistent with the occurrence of lower-
motor-neuron involvement, the main clinical feature
found in SMA-PME-affected individuals. Although the
p.Thr42Met substitution results in a mild deficiency of
acid-ceramidase activity, it is able to normalize the ceram-
ide level in Farber cells. This result suggests that the path-
ogenic mechanism underlying the CNS involvementThobserved in SMA-PME is probably unrelated to ceramide
accumulation in affected cells. However, the possibility
that, in specific cell types such as motor neurons, this
particular substitution results in changes of some ceramide
(or other sphingolipids) molecular species not detected by
the applied methods cannot yet be ruled out.
Medin et al.11 reported that the introduction of WT
human acid-ceramidase cDNA with a recombinant oncor-
etroviral vector into Farber-disease-cultured fibroblasts
restored enzyme activity completely and normalized ce-
ramide levels. Importantly, this study demonstrated that
transduced cells allowed diffusion of this enzyme into
the culture medium and that this activity could be taken
up subsequently into unmodified cells. More recently, a
preclinical Farber-disease gene-therapy study employing a
lentiviral vector has been performed on nonhuman
primates. Acid-ceramidase activity was detected above
normal levels in peripheral blood, bone-marrow cells, the
spleen, and the liver 1 year after lentiviral-vector transduc-
tion.24 These studies indicate that Farber disease and allelic
disease(s) such as SMA-PME might be candidates for gene
therapy in the near future. This underlines the importance
of ASAH1 or acid-ceramidase-activity screening in this
subgroup of SMA-affected individuals for diagnosis and
future therapeutics purposes.Supplemental Data
Supplemental Data include one figure and one table and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
This work was supported by the Association Franc¸aise contre les
Myopathies (to J.M.; ref. 14383 and 13860), the Institut National
de la Sante´ et de la Recherche Me´dicale (to J.M.), and Vaincre les
Maladies Lysosomales (to T.L.). The authors would like to thank
the Biomedical Institute of Biceˆtre for providing us with Sanger-
sequencing facilities, K. Sandhoff and H. Schulze (Bonn,
Germany) for providing the rabbit anti-ceramidase antibody, and
the National Heart, Lung, and Blood Institute Grand Opportunity
(GO) Exome Sequencing Project and its ongoing studies, the Lung
GO Sequencing Project (HL-102923), the Women’s Health Initia-
tive Sequencing Project (HL-102924), the Broad GO Sequencing
Project (HL-102925), the Seattle GO Sequencing Project (HL-
102926), and the Heart GO Sequencing Project (HL-103010),
which all produced and provided exome variant calls for compar-
ison. The authors wish to dedicate this work to the memory of
C. Brahe, who recently passed.
Received: January 10, 2012
Revised: March 12, 2012
Accepted: May 1, 2012
Published online: June 14, 2012Web Resources
The URLs for data presented herein are as follows:
BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgie American Journal of Human Genetics 91, 5–14, July 13, 2012 13
dbSNP, http://www.ncbi.nlm.nih.gov/snp
ESEfinder Release 2.0, http://rulai.cshl.edu/tools/ESE2/
Exome Variant Server, http://evs.gs.washington.edu/EVS/
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org
PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/References
1. Lefebvre, S., Bu¨rglen, L., Reboullet, S., Clermont, O., Burlet, P.,
Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani,
M., et al. (1995). Identification and characterization of a spinal
muscular atrophy-determining gene. Cell 80, 155–165.
2. Jankovic, J., and Rivera, V.M. (1979). Hereditary myoclonus
and progressive distal muscular atrophy. Ann. Neurol. 6,
227–231.
3. Haliloglu, G., Chattopadhyay, A., Skorodis, L., Manzur, A.,
Mercuri, E., Talim, B., Akc¸o¨ren, Z., Renda, Y., Muntoni, F.,
and Topaloglu, H. (2002). Spinal muscular atrophy with
progressive myoclonic epilepsy: Report of new cases and
review of the literature. Neuropediatrics 33, 314–319.
4. Ru¨schendorf, F., and Nu¨rnberg, P. (2005). ALOHOMORA: A
tool for linkage analysis using 10K SNP array data. Bioinfor-
matics 21, 2123–2125.
5. Abecasis, G.R., Cherny, S.S., Cookson, W.O., and Cardon, L.R.
(2002). Merlin—rapid analysis of dense genetic maps using
sparse gene flow trees. Nat. Genet. 30, 97–101.
6. Li, H., and Durbin, R. (2009). Fast and accurate short read
alignment with Burrows-Wheeler transform. Bioinformatics
25, 1754–1760.
7. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer,
N., Marth, G., Abecasis, G., and Durbin, R.; 1000 Genome
Project Data Processing Subgroup. (2009). The Sequence
Alignment/Map format and SAMtools. Bioinformatics 25,
2078–2079.
8. Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR:
Functional annotation of genetic variants from high-
throughput sequencing data. Nucleic Acids Res. 38, e164.
9. Bedia, C., Casas, J., Andrieu-Abadie, N., Fabria`s, G., and
Levade, T. (2011). Acid ceramidase expression modulates the
sensitivity of A375 melanoma cells to dacarbazine. J. Biol.
Chem. 286, 28200–28209.
10. Chatelut, M., Leruth, M., Harzer, K., Dagan, A., Marchesini, S.,
Gatt, S., Salvayre, R., Courtoy, P., and Levade, T. (1998).
Natural ceramide is unable to escape the lysosome, in contrast
to a fluorescent analogue. FEBS Lett. 426, 102–106.
11. Medin, J.A., Takenaka, T., Carpentier, S., Garcia, V., Basile, J.P.,
Segui, B., Andrieu-Abadie, N., Auge, N., Salvayre, R., and
Levade, T. (1999). Retrovirus-mediated correction of the meta-
bolic defect in cultured Farber disease cells. Hum. Gene Ther.
10, 1321–1329.14 The American Journal of Human Genetics 91, 5–14, July 13, 201212. Bedia, C., Camacho, L., Abad, J.L., Fabria`s, G., and Levade, T.
(2010). A simple fluorogenic method for determination of
acid ceramidase activity and diagnosis of Farber disease.
J. Lipid Res. 51, 3542–3547.
13. Sabourdy, F., Labauge, P., Stensland, H.M., Nieto, M., Garce´s,
V.L., Renard, D., Castelnovo, G., de Champfleur, N., and
Levade, T. (2009). A MANBA mutation resulting in residual
beta-mannosidase activity associated with severe leukoence-
phalopathy: a possible pseudodeficiency variant. BMC Med.
Genet. 10, 84.
14. Bielawska, A., Perry, D.K., and Hannun, Y.A. (2001). Determi-
nation of ceramides and diglycerides by the diglyceride kinase
assay. Anal. Biochem. 298, 141–150.
15. Westerfield, M. (1995). The zebrafish book. A guide for the
laboratory use of zebrafish (Danio rerio) (Eugene, OR: Univer-
sity of Oregon Press).
16. Nasevicius, A., and Ekker, S.C. (2000). Effective targeted gene
‘‘knockdown’’ in zebrafish. Nat. Genet. 26, 216–220.
17. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E.,
Gerasimova, A., Bork, P., Kondrashov, A.S., and Sunyaev, S.R.
(2010). A method and server for predicting damaging
missense mutations. Nat. Methods 7, 248–249.
18. Cartegni, L., Wang, J., Zhu, Z., Zhang, M.Q., and Krainer, A.R.
(2003). ESEfinder: A web resource to identify exonic splicing
enhancers. Nucleic Acids Res. 31, 3568–3571.
19. Furutani-Seiki, M., Jiang, Y.J., Brand, M., Heisenberg, C.P.,
Houart, C., Beuchle, D., van Eeden, F.J., Granato, M., Haffter,
P., Hammerschmidt, M., et al. (1996). Neural degeneration
mutants in the zebrafish, Danio rerio. Development 123,
229–239.
20. Melanc¸on, E., Liu, D.W., Westerfield, M., and Eisen, J.S.
(1997). Pathfinding by identified zebrafish motoneurons in
the absence of muscle pioneers. J. Neurosci. 17, 7796–7804.
21. Levade, T., Sandhoff, K., Schulze, H., and Medin, J.A. (2009).
Acid Ceramidase Deficiency: Farber Lipogranulomatosis. In
Scriver’s OMMBID (The Online Metabolic & Molecular Bases
of Inherited Disease), Valle, Beaudet, Vogelstein, Kinzler,
Antonorakis, and Ballabio, eds. (McGraw-Hill), http://www.
ommbid.com.
22. Samuelsson, K., and Zetterstro¨m, R. (1971). Ceramides in
a patient with lipogranulomatosis (Farber’s disease) with
chronic course. Scand. J. Clin. Lab. Invest. 27, 393–405.
23. Yeager, A.M., Uhas, K.A., Coles, C.D., Davis, P.C., Krause,W.L.,
and Moser, H.W. (2000). Bone marrow transplantation for
infantile ceramidase deficiency (Farber disease). Bone Marrow
Transplant. 26, 357–363.
24. Walia, J.S., Neschadim, A., Lopez-Perez, O., Alayoubi, A.,
Fan, X., Carpentier, S., Madden, M., Lee, C.J., Cheung, F.,
Jaffray, D.A., et al. (2011). Autologous transplantation of
lentivector/acid ceramidase-transduced hematopoietic cells
in nonhuman primates. Hum. Gene Ther. 22, 679–687.
